Radical Numerics Raises $50M for 'General Biological Intelligence'

San Francisco–based Radical Numerics emerged from stealth with a $50 million seed round led by Emergence Capital with participation from Obvious Ventures, Triatomic Capital, Factory, and First Spark Ventures, plus pre-seed backing from Stripe co-founder Patrick Collison. The startup, founded by the team behind Evo—one of the first AI models capable of reading and generating DNA sequences at scale—is building multimodal AI models it calls "general biological intelligence" that can reason across DNA, RNA, proteins and other biological data to accelerate drug discovery, diagnostics, and biosecurity.

The company previewed Omnii, its next-generation genome language model, alongside the funding. CEO Eric Nguyen acknowledged the dual mandate: "The same models that can help cure disease may also lower the barrier to designing harmful biology. These forces are inseparable." Crunchbase data shows that as frontier AI models grow more capable of designing biological systems, venture capital has poured tens of millions into startups promising both scientific acceleration and biodefense capabilities—a trend reflecting investor appetite for AI that can defend against AI-driven threats.

Architects tracking AI applications should note this signals a structural shift: life sciences AI is now table-stakes for both dual-use defense (biosecurity) and therapeutic impact. The market for multimodal bio-AI models remains nascent and competitive; capital concentration here (Radical Numerics, Isomorphic Labs, others) will shape which architectures and training approaches become standard-bearers for biological reasoning in the next 18–24 months.